# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## **Review Proposal Project**

### Technology Appraisal no. 52; Myocardial infarction – thrombolysis and Technology Appraisal no. 230; Myocardial infarction (persistent ST-segment elevation) - bivalirudin

### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Actavis UK (reteplase)	Board of Community Health Councils in
• Boehringer Ingelheim (tenecteplase,	Wales
alteplase)	British National Formulary
CSL Behring (streptokinase)	Care Quality Commission
The Medicines Company UK	Commissioning Support Appraisals
(bivalirudin)	Service
	Department of Health, Social Services
Patient/carer groups	and Public Safety for Northern Ireland
Action Heart	Healthcare Improvement Scotland
Afiya Trust	Medicines and Healthcare Products
Black Health Agency	Regulatory Agency
<ul> <li>Blood Pressure Association</li> </ul>	National Association of Primary Care
British Cardiac Patients Association	NHS Alliance
<ul> <li>British Hypertension Society</li> </ul>	NHS Commercial Medicines Unit
<ul> <li>Cardiac Risk in the Young</li> </ul>	NHS Confederation
Counsel and Care	<ul> <li>Public Health Wales NHS Trust</li> </ul>
<ul> <li>Equalities National Council</li> </ul>	Scottish Medicines Consortium
Grown Up Congenital Heart Patient's	
Association	Possible comparator manufacturers
<ul> <li>Heart Care Partnership (UK)</li> </ul>	Actavis UK (aspirin, clopidogrel)
HEART UK	Alliance Pharmaceuticals (aspirin)
<ul> <li>Muslim Council of Britain</li> </ul>	Aspar Pharmaceuticals (aspirin)
<ul> <li>Muslim Health Network</li> </ul>	Bayer (aspirin)
<ul> <li>National Obesity Forum</li> </ul>	Bristol-Myers Squibb Pharmaceuticals
Network of Sikh Organisations	(clopidogrel)
<ul> <li>South Asian Health Foundation</li> </ul>	Consilient Health (clopidogrel)
Specialised Healthcare Alliance	Dexcel-Pharma (aspirin, clopidogrel)
Stroke Association	Dr Reddy's Laboratories UK
Weight Concern	(clopidogrel)
	Eli Lilly (abciximab)
Professional groups	Focus Pharmaceuticals (aspirin)
British Association for Nursing in     Cording Core	Galpharm-International (aspirin)
Cardiac Care	Genus Pharmaceuticals (aspirin)
British Association for Services to the	GlaxoSmithKline (eptifibatide)

National Institute for Health and Clinical Excellence

Technology Appraisal no. 157; Myocardial infarction – thrombolysis and Technology Appraisal no. 230; Myocardial infarction (persistent ST-segment elevation) – bivalirudin Issue date: June 2012

Consultees	Commentators (no right to submit or appeal)
<ul> <li>Elderly</li> <li>British Association of Emergency Medicine</li> <li>British Atherosclerosis Society</li> <li>British Cardiac Intervention Society</li> <li>British Cardiovascular Society</li> <li>British Geriatrics Society</li> <li>British Heart Foundation</li> <li>British Nuclear Cardiology Society</li> <li>British Nuclear Cardiology Society</li> <li>British Society of Cardiac Radiology</li> <li>National Heart Forum (UK)</li> <li>Nurses Hypertension Association</li> <li>Primary Care Cardiovascular Society</li> <li>Royal College of General Practitioners</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Physicians</li> <li>Royal College of Physicians</li> <li>Royal Society of Medicine</li> <li>Society for Cardiological Science and Technology [BCS affiliated]</li> <li>Society of Cardiothoracic surgeons</li> <li>United Kingdom Clinical Pharmacy Association</li> <li>Vascular Society</li> <li>Others</li> <li>Cornwall and Isles of Scilly PCT Cluster</li> <li>Department of Health</li> <li>Hywel Dda Health Board</li> <li>Welsh Government</li> </ul>	<ul> <li>Kent Pharmaceuticals (aspirin)</li> <li>Merck Sharp &amp; Dohme (tirofiban)</li> <li>Mylan (aspirin, clopidogrel)</li> <li>Napp Pharmaceuticals (aspirin)</li> <li>Pinewood Healthcare (aspirin)</li> <li>Reckitt Benckiser (aspirin)</li> <li>Sandoz (aspirin, clopidogrel)</li> <li>Sinclair Pharma (aspirin)</li> <li>Teva UK (aspirin, clopidogrel)</li> <li>The Boots Company (aspirin)</li> <li>Thornton &amp; Ross (aspirin)</li> <li>Watson Pharmaceuticals (aspirin, clopidogrel)</li> <li>Wockhardt UK (aspirin, heparin)</li> </ul> Relevant research groups <ul> <li>Antithrombotic Trialists' (ATT) collaboration</li> <li>British Society for Cardiovascular Research [BCS affiliated]</li> <li>Cardiac and Cardiology Research Dept, Barts</li> <li>Cardiovascular Diseases Specialist Library (CVDSL)</li> <li>Cardiovascular Research Initiative, University of Oxford</li> <li>Cochrane Heart Group</li> <li>Cochrane Stroke Group</li> <li>Cochrane Stroke Group</li> <li>CORDA</li> <li>European Council for Cardiovascular Research</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for the Care of Older People</li> </ul>
	<ul> <li>Assessment Group tbc</li> <li>Evidence Review Group tbc</li> <li>National Institute for Health Research</li> </ul>

National Institute for Health and Clinical Excellence Technology Appraisal no. 157; Myocardial infarction – thrombolysis and Technology Appraisal no. 230; Myocardial infarction (persistent ST-segment elevation) – bivalirudin Issue date: June 2012

Consultees	Commentators (no right to submit or appeal)
	Health Technology Assessment Programme
	<ul> <li>Associated Guideline Groups</li> <li>National Clinical Guideline Centre</li> <li>National Collaborating Centre for Chronic Conditions</li> </ul>
	<ul><li><u>Associated Public Health Groups</u></li><li>None</li></ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

### **Definitions:**

#### **Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

#### **Commentators**

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

#### Assessment Group

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).